≈ 500 mg/day (or 2S-hesperidin), in studies of 3–6 weeks.
Improves cardiovascular risk markers and lowers inflammation (TNF-α); the effect on blood pressure is inconsistent.
View the study (meta-analysis) →Some meta-analyses see reductions in LDL and triglycerides; mixed results.
⏱ 2 min read
Hesperidin is a flavonoid found in large amounts in the white peel and pulp of citrus fruits (especially oranges, mandarins, and lemons), extracted industrially as a byproduct of citrus juice production; for decades it has been used clinically in Europe for chronic venous insufficiency, capillary fragility, and hemorrhoids, a traditional indication whose evidence base has been consolidating through modern trials on its effect on endothelial function and microcirculation.
Unlike many polyphenol supplements whose main problem is low oral bioavailability, hesperidin is converted in the small intestine into hesperetin by enzymatic action and by the microbiota, and this form is well absorbed into the bloodstream; modern formulations with micronized hesperidin or hesperidin complexed with beta-cyclodextrin significantly improve bioavailability and are the ones used in the clinical trials with the best results.
The indication with the longest clinical history is chronic venous insufficiency, especially in combination with diosmin (another citrus flavonoid): the micronized purified flavonoid fraction (MPFF, known commercially as Daflon in Europe) is one of the most prescribed venotonics in the world, at doses of 1,000 milligrams daily (450 mg diosmin + 50 mg hesperidin expressed as hesperidin) for months, showing significant improvements in leg heaviness, evening edema, and quality of life.
The mechanism combines improved venous tone (a modest vasoconstrictive effect on dilated veins), reduced capillary permeability (which improves the edema associated with venous stasis), and an anti-inflammatory effect on the microvascular endothelium; this multimodal profile explains why the clinical response is more sustained than that of single-mechanism venotonics.
Several trials have shown significant improvements in flow-mediated dilation (a functional marker of the endothelium) with doses of 500-1,000 milligrams daily of hesperidin over 4-12 weeks, especially in people with metabolic syndrome or cardiovascular risk factors; these effects are associated with modest reductions in inflammatory markers (CRP, ICAM-1, VCAM-1) and improvements in lipid profile that suggest a real cardioprotective role with prolonged use.
In acute hemorrhoidal attacks, the diosmin+hesperidin combination at high doses (3,000 mg/day for 4 days, then 2,000 mg/day for 3 days) significantly reduces pain, bleeding, and the duration of the episode; this use is well established in European proctology, and the flavonoid fraction is included in clinical guidelines for the medical management of hemorrhoids as a first- or second-line option.
The doses studied range from 500 to 3,000 milligrams daily depending on the indication: 500-1,000 mg/day for chronic venous insufficiency or endothelial function, higher doses in acute hemorrhoidal attacks; ideally divided into two or three doses with meals; micronized products or those complexed with cyclodextrin are the best supported by direct clinical evidence.
Generally very well tolerated; adverse effects are rare and mild (digestive discomfort, occasionally headache); people taking anticoagulants should use caution because of a mild antiplatelet effect and possible interactions with warfarin (hesperidin may modulate hepatic cytochrome P450 at high doses); caution is advisable in pregnancy and breastfeeding because of limited data on reproductive safety, although the flavonoid fraction has traditionally been used in women with varicose veins of pregnancy under medical supervision.
Information, not medical advice. Scientific evidence reflects the quality of the studies.